/PRNewswire/ Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for, and type 2 diabetes (T2D).
/PRNewswire/ Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor.